GBM cells themselves release interleukin 6 (IL-6), which is necessary for myeloid PD-L1 induction through a signal transducer and activator of transcription 3 (STAT3)-dependent fashion and disrupting IL6 signaling enhances immune-mediated antitumor effects against GBM (28). Here, STAT3 is linked to glioblastoma.